Unlocking Long-Term Wealth: 3 Stocks to Buy and Hold
Investing in companies with in-demand products and a long-term perspective can lead to substantial gains. While market timing is a challenging feat, the buy-and-hold strategy often delivers positive results over time. The key is to identify well-managed companies offering highly sought-after products. The healthcare sector presents numerous opportunities, but it's crucial to recognize that today's industry leaders may not be the optimal choice.
Here's why Intuitive Surgical (ISRG) stands out as an attractive investment, how Eli Lilly (LLY) mirrors Pfizer's (PFE) potential, and why Johnson & Johnson (JNJ) is a safe haven for conservative investors.
Surgical Robotics: A Growing Market
Intuitive Surgical's surgical robots experienced a 13% expansion in their installed base during the third quarter of 2025, while the number of surgeries performed with these robots increased by 20%. With a significant portion of the company's revenue coming from parts and services for its robots, Intuitive Surgical operates like an annuity, offering a substantial growth opportunity. However, its lofty price-to-earnings (P/E) ratio of 74 may deter some investors.
Medtronic's Advantage
Medtronic, a competitor in the surgical robotics space, boasts a much lower P/E ratio of 28. While surgical robots are a relatively new product for Medtronic, the company's diversified medical device portfolio is a strength. Medtronic's growth is supported by the replication of Intuitive Surgical's success, and its focus on streamlining its business by prioritizing its most profitable products. Additionally, Medtronic's proven track record, marked by 48 consecutive annual dividend increases, makes it an attractive long-term investment with a 2.7% dividend yield.
Eli Lilly's Success Story
Eli Lilly's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss), have become a gold mine, contributing over 50% of the company's sales in the third quarter of 2025. The stock's success has driven its P/E ratio to a lofty 53, indicating high investor expectations. However, Pfizer's P/E of around 15 suggests lower investor confidence, which is understandable given its patent cliff approaching and a somewhat weak pipeline.
Pfizer's Strategic Move
Pfizer is addressing its concerns by acquiring Metsera, a competitor with an attractive drug pipeline, particularly in the weight loss space. This strategic move showcases Pfizer's ability to adapt and grow, making it a potential long-term investment despite its current challenges. Eli Lilly's success may not be sustainable, and Pfizer could be the next industry leader.
Johnson & Johnson: A Dividend King
For investors seeking a safe haven, Johnson & Johnson, a leader in both the pharmaceutical and medical device sectors, offers a compelling option. With a history of over five decades of annual dividend increases, J&J is a Dividend King, currently providing a 2.5% dividend yield, more than twice that of the S&P 500 index. Its relatively modest P/E ratio of 20 makes it an attractive long-term investment, offering a balanced approach between growth and stability.
The Bottom Line
While Intuitive Surgical and Eli Lilly are currently in the spotlight, their long-term prospects may not justify premium prices. Medtronic and Pfizer, with their value propositions, could be preferable options in the medical device and pharmaceutical niches. Johnson & Johnson, with its diversified portfolio and strong dividend history, provides a reliable long-term investment strategy, offering a smooth ride for investors.
